George Dudnik, 36, was diagnosed with stage four ROS1-positive lung cancer in November after being told he was 'too young and ...
George Dudnik, 36, was told he was far too young and fit to be diagnosed with cancer – but after a series of terrifying ...
In October, a CT scan unveiled several troublesome spots in his right lung, and a subsequent surgery in November left him ...
The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...
During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new nonclinical data for taletrectinib in ROS1-positive ...
First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...
George Dudnik was diagnosed with stage four lung cancer in November – and was told he would die from it despite being ...
The Food and Drug Administration (FDA) has only approved ceritinib (Zykadia) and lorlatinib (Lorbrena) to treat ALK-positive lung cancer. However, a doctor may still prescribe if you have ROS1 ...
A fit and healthy young man has been told he has incurable cancer after an initial frightening warning sign. George Dudnik, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results